A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

Trial Profile

A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Investigate The Clinical Efficacy And Safety of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2016

At a glance

  • Drugs Peptide p277 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DIA-AID; DIA-AID-1
  • Sponsors Andromeda Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2014 Results published in the Diabetes Care.
    • 25 Jun 2013 Preliminary results from the open-label extension study presented at the 73rd Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top